EXOZ vs NUVB vs BEAM vs CRSP vs NTLA

For growth investors, Nuvation Bio Inc.

(NUVB) is the stronger pick with 699. 0% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Analysts rate Nuvation Bio Inc. (NUVB) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, eXoZymes, Inc.

(EXOZ) delivered a total return of +15. 6%, compared to -79. 8% for Intellia Therapeutics, Inc. (NTLA). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus NUVB's -52. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), eXoZymes, Inc.

(EXOZ) is the lower-risk stock at 0. 92β versus Intellia Therapeutics, Inc. 's 2. 21β — meaning NTLA is approximately 139% more volatile than EXOZ relative to the S&P 500. On balance sheet safety, Nuvation Bio Inc. (NUVB) carries a lower debt/equity ratio of 3% versus 24% for Beam Therapeutics Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nuvation Bio Inc.

(NUVB) is pulling ahead at 699. 0% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -188. 0% for eXoZymes, Inc.. Over a 3-year CAGR, CRSP leads at 100. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

eXoZymes, Inc.

(EXOZ) is the more profitable company, earning 0. 0% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EXOZ leads at 0. 0% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — NUVB leads at 86. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, eXoZymes, Inc.

(EXOZ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 92)). Intellia Therapeutics, Inc. (NTLA) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EXOZ: +11. 2%, NTLA: -41. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EXOZ is a small-cap quality compounder stock; NUVB is a small-cap high-growth stock; BEAM is a small-cap high-growth stock; CRSP is a small-cap quality compounder stock; NTLA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.